Related Experiment Videos
[Evidence-based medicine tratment of chronic viral hepatitis B and C]
D Ledro Cano1, M Gómez Parra, M Jiménez Sáenz
1Servicio de Aparato Digestivo, Area Hospitalaria Virgen Macarena, Sevilla.
Insights
Chronic viral hepatitis B and C cause significant liver disease globally. This review analyzes current treatments to find cost-effective, evidence-based approaches for better patient outcomes.
Area of Science:
- Hepatology
- Virology
- Internal Medicine
Context:
- Viral hepatitis remains a leading global cause of jaundice, chronic liver disease, cirrhosis, and hepatocellular carcinoma.
- Despite advances, treatments for viral hepatitis B and C are often unsatisfactory, costly, and long-term.
- These conditions contribute significantly to the burden of liver disease and healthcare resource utilization worldwide.
Purpose:
- To review and analyze current drugs and therapeutic schedules for chronic viral hepatitis B and C.
- To evaluate the response rates and effectiveness of different treatment regimens.
- To provide an evidence-based medicine approach for optimizing the benefit/cost ratio in managing chronic viral hepatitis.
Summary:
- This review examines various pharmacological agents and treatment protocols employed for chronic viral hepatitis B and C.
- It assesses the clinical responses achieved with different therapeutic strategies.
- The analysis focuses on identifying the most effective and cost-efficient treatment options.
Impact:
- Highlights the need for evidence-based medicine in managing chronic viral hepatitis.
- Aims to guide clinicians toward more cost-effective treatment decisions.
- Contributes to optimizing patient care and resource allocation for viral hepatitis management.
Abstract:
Worldwide, viral hepatitis is the most common cause of jaundice, chronic liver disease, cirrhosis and hepatocellular carcinoma. Although mayor advances have been made in the field of treatment and prevention, there is not a totally satisfactory treatment for each of both diseases. They account for a high percentage of the etiology of viral hepatitis and have a tendency towards chronicity and developing cirrhosis, resulting in a tremendous waste of medical resources. On the other hand, their treatments are long-term ones and the drugs, which are employed, are expensive. Thus, it is necessary to make an evidence-based medicine approach in this particular kind of illness to obtain the best benefit/cost ratio. In this current review, we analyzed the different drugs and therapeutic schedules, which are used in the chronic viral hepatitis B and C, and as well as their obtained response.